Abstract
Introduction: Neonatal pulmonary hemorrhage (PH) is a clinical picture with various risk factors playing a role in its etiology and has a high neonatal mortality and morbidity rate. In this paper, we share the results of Ankaferd blood stopper (ABS) use in the treatment of neonatal PH.
Materials and methods: In this retrospective cross-sectional study, data were obtained using the patient file and automation systems. Two patients whose pulmonary bleeding was stopped by administering ABS between July 2018 and July 2020 in the neonatal intensive care unit were included in the study.
Results: The first patient was a male baby born by cesarean section at 38 3/7 weeks of gestation and weighing 3320 g. Massive PH was detected in the patient who developed cyanosis at the 3rd hour of maternal side follow-up. Despite endotracheal tube (ETT) aspiration, pulmonary bleeding continued, and the bleeding stopped immediately after ABS was used. The other patient was a male baby born by cesarean section at 33 6/7 weeks of gestation. Postpartum prematurity, respiratory distress syndrome, and neonatal sepsis were diagnosed and massive PH developed on the 9th day of follow-up. The bleeding stopped immediately after ABS was administered to the patient.
Conclusion: There is still no effective drug or method to treat PH in the neonatal period. ABS—a new treatment option—may be beneficial in reducing mortality and morbidity.

Key words: Ankaferd Blood Stopper (ABS), pulmonary hemorrhage treatment, neonate